Massard, S.
114  Ergebnisse:
Personensuche X
?
1

Passive Enhancement of Retinol Skin Penetration by Jojoba O..:

Gruber JV ; Terpak N ; Massard S..
https://www.dovepress.com/passive-enhancement-of-retinol-skin-penetration-by-jojoba-oil-measured-peer-reviewed-fulltext-article-CCID.  , 2023
 
?
2

Modification des représentations sociales des métiers d'inf..:

Gandon, L ; Hardy-Massard, S
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.prps.2018.06.002.  , 2019
 
?
3

Modification des représentations sociales des métiers d'inf..:

Gandon, L ; Hardy-Massard, S
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.prps.2018.06.002.  , 2019
 
?
5

Pembrolizumab plus olaparib in patients with metastatic cas..:

Yu, Evan Y ; Piulats, Josep M ; Gravis, Gwenaelle...
Yu , E Y , Piulats , J M , Gravis , G , Fong , P C C , Todenhöfer , T , Laguerre , B , Arranz , J A , Oudard , S , Massard , C , Heinzelbecker , J , Nordquist , L T , Carles , J , Kolinsky , M P , Augustin , M , Gurney , H , Tafreshi , A , Li , X T , Qiu , P , Poehlein , C H , Schloss , C & de Bono , J S 2023 , ' Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer : long-term results from the phase 1b/2 KEYNOTE-365 Cohort A study ' , European Urology , vol. 83 , no. 1 , pp. 15-26 . https://doi.org/10.1016/j.eururo.2022.08.005.  , 2023
 
?
6

An International Comparison of Presentation, Outcomes and C..:

Wysocki, Oskar ; Zhou, Cong ; Rogado, Jacobo...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14163931.  , 2022
 
?
8

Access to early-phase clinical trials in older patients wit..:

Baldini, C ; Charton, E ; Schultz, E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271476/.  , 2022
 
?
9

Establishment of CORONET, COVID-19 Risk in Oncology Evaluat..:

Lee, RJ ; Wysocki, O ; Zhou, C...
JCO Clinical Cancer Informatics, 2022, 6 (6), pp. e2100177 -.  , 2022
 
?
10

Establishment of CORONET, COVID-19 Risk in Oncology Evaluat..:

Lee, Rebecca J ; Wysocki, Oskar ; Zhou, Cong...
info:eu-repo/semantics/altIdentifier/doi/10.1200/CCI.21.00177.  , 2022
 
?
11

Isatuximab plus atezolizumab in patients with advanced soli..:

Simonelli, M ; Garralda, E ; Eskens, F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588873/.  , 2022
 
?
12

An international comparison of presentation, outcomes and C..:

Wysocki, O ; Zhou, C ; Rogado, J...
https://eprints.whiterose.ac.uk/207708/1/An%20International%20Comparison%20of%20Presentation,%20Outcomes%20and%20CORONET%20Predictive%20Score%20Performance%20in%20Patients%20with%20Cancer%20Prese.pdf.  , 2022
 
?
13

Establishment of CORONET, COVID-19 Risk in Oncology Evaluat..:

Lee, Rebecca J ; Wysocki, Oskar ; Zhou, Cong...
info:eu-repo/semantics/altIdentifier/doi/10.1200/CCI.21.00177.  , 2022
 
?
14

Establishment of CORONET, COVID-19 Risk in Oncology Evaluat..:

Lee, Rebecca J ; Wysocki, Oskar ; Zhou, Cong...
info:eu-repo/semantics/altIdentifier/doi/10.1200/CCI.21.00177.  , 2022
 
?
15

Establishment of CORONET, COVID-19 Risk in Oncology Evaluat..:

Lee, Rebecca J ; Wysocki, Oskar ; Zhou, Cong...
info:eu-repo/semantics/altIdentifier/doi/10.1200/CCI.21.00177.  , 2022
 
1-15